Glycosylated end-products and peritoneal membrane damage

Dialysis and Transplantation

Volumn 27, Issue 2, 1998, Pages 79-86

  Dasgupta, Mrinal K ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED ALBUMIN; GLYCOSYLATED END PRODUCT; UNCLASSIFIED DRUG;

DIABETES MELLITUS; HYPERGLYCEMIA; HYPOALBUMINEMIA; MEMBRANE PERMEABILITY; MESOTHELIUM; PERITONEAL DIALYSIS; PERITONEUM; PERITONITIS; PRIORITY JOURNAL; REVIEW; ULTRAFILTRATION;

EID: 0031910591     PISSN: 00902934     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (12)

1. Bucala R, Vlassara H. Advanced glycosylation end-products in diabetic renal and vascular disease. Am J Kid Dis 1995; 26:875-888.
2. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end-products in tissue and the biochemical basis of diabetic complications. N Eng J Med 1988; 318:1315-1321.
3. Korbet SM, Makita Z, Firanek CA, Vlassara H. Advanced glycosylation end-products in continuous ambulatory peritoneal dialysis patients. Am J Kid Dis 1993; 22:588-591.
4. Ateshkadi A, Johnson CA, Founds WA, Zimmerman SW. Serum advanced glycosylation end-products in haemodialysis and CAPD. Perit Dial Int 1995; 15:129-133.
5. Lamb EJ, Cartel WR, Dawnay AB. In vitro formation of advanced glycation end-products in peritoneal dialysis fluid. Kidney Int 1995; 47 1768-1774.
6. Dawnay AB. Advanced glycation end-products in peritoneal dialysis. Perit Dial Int 1996; 16:S50-S53.
7. Dobbie JW, Lloyd JK, Gall CA. Categorization of ultrastructural changes in peritoneum mesothelium stroma and blood vessels in uraemia and CAPD patients. In: Khanna R, Nolph KD, Prowant B, Twardowski ZJ, Oreopoulos DG (eds.), Advances In Continuous Ambulatory Peritoneal Dialysis, Toronto: University of Toronto Press, 1990, pp 3-12.
8. Dobbie JW, Anderson JD, Hind C. Long-term effects of peritoneal dialysis on peritoneal morphology. Perit Dial Int 1994; 14:S3, S16-S20.
9. Lee WK, Akyol M, Shaw S, Dominiczak MH, Briggs JD. Kidney transplantation decreases the tissue level of advanced glycosylation end-products. Nephrol Dial Transplant 1995; 10:103-107.
10. Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takazoe K, et al. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997; 51:182-186.
11. Blake PG, Somblos K, Izzatt S, Oreopoulos DG. Low serum albumin predicts poor outcome in CAPD and is related to high peritoneal permeability. J Am Soc Nephrol 1990; 1:383.
12. Churchill DN, Thorpe KE, Nolph KD, Oreopoulos DG, Page D, Keshaviah PR (for the CANUSA PD Study Group). CAPD patient and technique survivals are worse with increased membrane permeability. Perit Dial Int 1996; 16(Suppl 2):S21.